Preventative Cardiology, Baker Heart Research Institute, Melbourne, Australia.
J Clin Nurs. 2009 Mar;18(5):678-86. doi: 10.1111/j.1365-2702.2008.02507.x. Epub 2008 Nov 25.
Community awareness of the importance of hypercholesterolemia and the need for appropriate therapy is an important part of global efforts to reduce the population burden of cardiovascular disease. The aim of this study was to assess the knowledge and attitudes about cholesterol and to determine adherence to taking cholesterol-lowering medication among patients at high risk for cardiovascular events.
In spite of the availability of lifestyle and medical treatments for lipid management, an estimated 50% of adult Australians (6.4 million) remain at risk for a cardiovascular-related event because they have total blood cholesterol levels which exceed recommended limits. It is within this context that a significant gap remains in meeting cholesterol goals, despite easy to meet targets with readily available therapeutic options.
A two-page national self-report postal survey was conducted from August-October 2006.
A total of 508 Australian adults previously treated for hypercholesterolemia were surveyed to determine their understanding about cholesterol and their adherence to treatment. The mean age of participants was 67 (SD 10) years (72% male). Many participants (72%) were at risk of a cardiovascular event based on a prior history and 18% had type II diabetes.
Participants had been prescribed lipid-lowering therapy (94% statin therapy) for an average of 10 years and visited their general practitioner on average three times per year. For those who knew their most recent cholesterol reading (67%), the total cholesterol was on average 4.5 (SD 1.1) mmol/l. This level was above the recommended limits for 40% of participants. Overall, 85% of participants reported knowing that there was high- and low-density lipoprotein forms of cholesterol, but only 56% and 38%, respectively, said that they understood or showed signs of clearly understanding the different types of cholesterol when their knowledge was assessed further. On the whole, therefore, participants had a limited understanding about cholesterol and its potential impact on cardiovascular events. Moreover, 25% of participants admitted to being non-compliant in taking their medication and only 51% correctly identified modifiable risk factors as most important for heart disease. Encouragingly, despite 85% of participants finding lifestyle changes challenging, most still identified their potential benefits.
This study highlights that there are many unresolved issues in relation to educating high-risk patients who regularly visit their general practitioner to learn about and optimise their cholesterol levels via appropriate treatment and monitoring.
There is a need for urgent public education and management by individuals and the health community. Strategies to address 'cholesterol complacency', in the sense of a willingness to accept sub-optimal standards of cholesterol control at both the patient and healthcare system levels (general practitioners in particular), are urgently needed to truncate an anticipated rising tide of cardiovascular disease in Australia.
提高公众对高胆固醇血症重要性和适当治疗必要性的认识,是降低心血管疾病人群负担的全球努力的重要组成部分。本研究旨在评估患者对胆固醇的了解和态度,并确定高危心血管事件患者对降胆固醇药物的依从性。
尽管有生活方式和药物治疗可用于血脂管理,但据估计,50%的澳大利亚成年人(640 万)仍面临心血管相关事件的风险,因为他们的总胆固醇水平超过了建议的限值。在这种情况下,尽管有容易达到的治疗目标,但仍存在显著的差距,无法达到胆固醇目标。
2006 年 8 月至 10 月期间进行了一项全国性的两页自我报告邮寄调查。
调查了 508 名曾接受过高胆固醇血症治疗的澳大利亚成年人,以确定他们对胆固醇的了解程度和对治疗的依从性。参与者的平均年龄为 67(SD 10)岁(72%为男性)。根据既往病史,72%的参与者有发生心血管事件的风险,18%患有 2 型糖尿病。
参与者平均接受降脂治疗(94%为他汀类药物治疗)10 年,平均每年就诊全科医生 3 次。对于那些知道最近胆固醇检测结果(67%)的人,总胆固醇平均为 4.5(SD 1.1)mmol/L。这一水平高于 40%参与者的推荐限值。总的来说,85%的参与者报告说知道有高密度脂蛋白和低密度脂蛋白两种形式的胆固醇,但只有 56%和 38%的参与者在进一步评估其知识时表示理解或表现出对不同类型胆固醇的明显理解。因此,总的来说,参与者对胆固醇及其对心血管事件的潜在影响的了解有限。此外,25%的参与者承认不遵医嘱服药,只有 51%的参与者正确识别出可改变的危险因素是心脏病最重要的危险因素。令人鼓舞的是,尽管 85%的参与者认为改变生活方式具有挑战性,但大多数人仍认为其具有潜在益处。
本研究表明,在教育经常就诊的高危患者了解和优化胆固醇水平方面,通过适当的治疗和监测,还有许多未解决的问题。
需要对个人和卫生界进行紧急的公众教育和管理。需要采取策略来解决“胆固醇自满”问题,即患者和医疗保健系统(特别是全科医生)都愿意接受亚最佳胆固醇控制标准,以遏制澳大利亚心血管疾病预期上升的浪潮。